Semaglutide

Semaglutide is a TGA-registered, prescription-only GLP-1 receptor agonist used for type 2 diabetes and chronic weight management. The trial evidence is unusually strong — roughly 15% average weight loss over 68 weeks, and a genuine reduction in cardiovascular events in the SELECT trial. The parts that get less airtime: most of the weight comes back when it stops, a meaningful share of what is lost is lean tissue, gastrointestinal side effects drive real discontinuation, and compounded copies sold in Australia have been a documented safety hazard.

What semaglutide is

Semaglutide is a synthetic analogue of glucagon-like peptide-1 (GLP-1), a hormone your gut already releases when you eat. It is a GLP-1 receptor agonist: a molecule engineered to activate the same receptor as the natural hormone, but to survive in the bloodstream long enough to be a medicine rather than a signal that lasts a couple of minutes.

In Australia it is registered under two brand names for two different purposes — one for type 2 diabetes, one for chronic weight management in eligible adults — with an oral formulation also available. All are Schedule 4, prescription-only medicines. Which registration applies to you determines eligibility, subsidy and supply.

It is not a fat burner and not something that works independently of what you eat: every trial result below was produced alongside structured diet and activity support.

How it works

Native GLP-1 is secreted by enteroendocrine L cells lining the lower small intestine and colon when nutrients arrive, then destroyed within about a minute by an enzyme called DPP-4. That fragility is the problem semaglutide was designed around: it carries a modification that resists DPP-4 cleavage and a fatty acid chain that binds it reversibly to albumin, giving it a circulating half-life measured in days rather than minutes.

The GLP-1 receptor is a G-protein-coupled receptor that triggers cyclic AMP signalling inside the target cell. Three consequences matter clinically:

1. Glucose-dependent insulin release. In pancreatic beta cells, GLP-1 receptor activation amplifies insulin secretion — but only when blood glucose is already elevated — and suppresses glucagon in a similarly glucose-dependent way. This is why semaglutide lowers glucose without, on its own, causing much hypoglycaemia: the effect switches off as glucose normalises. The exception is combination with insulin or sulfonylureas, which are not glucose-dependent; then hypoglycaemia is a real risk and those medicines need adjusting.

2. Slowed gastric emptying. Food leaves the stomach more slowly, so meals feel larger and fullness lasts longer. This contributes to early satiety — and to most of the nausea. It also attenuates over time as the body adapts, which is one reason the appetite benefit persists after the initial gastric effect fades.

3. Central appetite regulation — the main event. This is where the durable weight effect comes from. GLP-1 receptors are expressed in the arcuate nucleus of the hypothalamus and in the area postrema and nucleus tractus solitarius of the brainstem — regions outside the tightest part of the blood–brain barrier, and therefore reachable by a large circulating peptide. Activation there stimulates POMC/CART neurons, which promote satiety, and indirectly inhibits the AgRP/NPY neurons that drive hunger. What patients describe — reduced appetite, smaller portions feeling sufficient, a quieting of intrusive thoughts about food — maps onto this central action.

The unwelcome corollary: the area postrema is also the brain's nausea and vomiting trigger zone. The appetite mechanism and the main side effect share an anatomical address. That is why the amount given is increased in stages under supervision rather than started at full treatment level.

What the human evidence actually shows

Semaglutide has one of the stronger evidence bases in this field, which makes it worth stating both halves honestly.

Weight loss is large and replicated. In the pivotal STEP-1 trial, adults with obesity and without type 2 diabetes lost an average of about 14.9% of body weight over 68 weeks, against roughly 2.4% on placebo, with lifestyle support in both arms. Across the wider STEP programme, average reductions of roughly 10–18% were reported, with smaller effects in people who also have type 2 diabetes. In the head-to-head SURMOUNT-5 trial against tirzepatide, semaglutide produced around 15% at 72 weeks.

It reduces hard cardiovascular outcomes. The SELECT trial randomised people with overweight or obesity and established cardiovascular disease, but without diabetes, and found a roughly 20% reduction in major adverse cardiovascular events over several years. That is a genuinely different class of evidence from a weight number, and it moved semaglutide from a weight medicine to a cardiometabolic one. Kidney-outcome and heart-failure trials have added to that picture; see GLP-1s beyond weight loss.

Now the inconvenient parts.

The weight comes back. This is the most under-communicated fact about the class. In an extension of STEP-1, participants who stopped regained roughly two-thirds of the weight they had lost within about a year, and the cardiometabolic improvements largely reverted with it. A separate withdrawal trial showed the same pattern. Semaglutide treats obesity the way antihypertensives treat blood pressure: it works while you take it. Anyone planning around a short course should understand that upfront.

Gastrointestinal side effects are close to universal and drive real discontinuation. In STEP-1 around three-quarters of participants reported nausea, vomiting, diarrhoea or constipation. Most were mild-to-moderate and clustered around the escalation phase, but adverse events led several times more people to stop than on placebo — and real-world discontinuation runs considerably higher than in trials, where participants had structured support.

A meaningful share of the weight lost is lean tissue. Body composition sub-studies show fat mass falling proportionally more, but absolute lean mass falls too — commonly cited between a quarter and nearly 40% of total weight lost, broadly what is seen with substantial weight loss by any means. Whether that translates into functional loss, and how far resistance training and adequate protein offset it, is genuinely unresolved. It is a legitimate concern, not a marketing point for supplements.

Supply has been unreliable. Well-documented global shortages affected Australian patients for an extended period, at one point prompting advice to prioritise people with type 2 diabetes.

Other signals under watch. Gallstones (partly a consequence of rapid weight loss itself), pancreatitis, and a rare eye condition — non-arteritic anterior ischaemic optic neuropathy — examined by regulators as a possible very rare association. These positions have changed recently; confirm the current product information with your prescriber.

Regulatory status in Australia

Semaglutide is TGA-registered — evaluated for quality, safety and efficacy, with an approved Product Information document setting out indications, contraindications, interactions and warnings. That document is the practical difference between a registered medicine and everything else in this category.

PBS subsidy is limited. The diabetes indication has been PBS-listed under restricted criteria. Weight management has generally not been subsidised, meaning people using it for weight typically pay the full private price plus consultations. Listings and criteria in this class have changed repeatedly — confirm the current position with your prescriber or on the PBS schedule rather than relying on any summary.

Compounded semaglutide is the serious problem. During the shortages, Australian compounding pharmacies produced "semaglutide" preparations sold at lower prices. The TGA acted: pharmacy compounding of GLP-1 receptor agonists was prohibited from late 2024. The reasons are worth understanding rather than taking on trust:

• The preparation has not been TGA-evaluated for identity, purity, sterility or potency.
• Some products used salt forms of semaglutide never tested in humans.
• Concentration errors in unregulated products have caused documented overdoses and hospitalisations internationally.
• There is no approved Product Information, no pharmacovigilance pathway, and no manufacturer accountability.

The TGA has separately issued alerts about counterfeit product entering supply chains — including pens labelled as semaglutide that contained insulin, a substitution capable of causing life-threatening hypoglycaemia. Anything bought online, imported, or supplied through a gym or social media seller carries no assurance whatsoever of what is in it. If price is the reason a preparation is being offered to you, that is the question to ask about. Compounded vs TGA-registered medicines sets out how to tell the difference.

Australian law also restricts advertising prescription-only medicines to the public: a clinic may discuss semaglutide inside a consultation, but publicly promoting it with promised results is a different thing.

Who it is for — and who it is not for

Registered use covers adults with type 2 diabetes, and adults with obesity or overweight plus a weight-related health condition, alongside diet and physical activity. Given SELECT, the more meaningful question is increasingly cardiometabolic risk rather than weight alone.

It is not appropriate, or needs specialist care, in: pregnancy, breastfeeding, or planned near-term conception; a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, on the basis of rodent thyroid C-cell findings; previous pancreatitis; severe gastrointestinal disease or gastroparesis; type 1 diabetes, where it is not a substitute for insulin; and active or past eating disorders, where appetite suppression can be genuinely harmful. People taking insulin or sulfonylureas need those reviewed at the same time.

Two practical points are easy to miss. Tell any anaesthetist or endoscopist that you take it — delayed gastric emptying has been linked to retained stomach contents and aspiration risk. And if low testosterone is part of your picture, obesity and sleep apnoea both suppress the hormonal axis described in our TRT guide; weight loss sometimes improves those numbers without hormone therapy.

Risks, monitoring and cost

Expect baseline assessment, closer review during the escalation period when side effects peak, then ongoing review of weight, glucose where relevant, blood pressure, tolerability, and whether the treatment is still delivering enough to justify its cost and risk. A credible prescriber sets a stopping rule as well as a starting one. Serious but less common concerns include pancreatitis, gallbladder disease, kidney injury following dehydration from vomiting or diarrhoea, and hypoglycaemia alongside certain diabetes medicines; severe or persistent abdominal pain warrants prompt attention.

Absent PBS subsidy, the realistic cost is an ongoing private medicine expense plus consultations plus pathology — indefinitely, given the regain data. Telehealth weight services often add a programme fee. Ask for the annual total in writing before starting.

What to ask a doctor

• Which registered indication applies to me, and why this rather than another option?
• Is what you are prescribing a TGA-registered product, or a compounded or imported preparation?
• Am I eligible for any PBS subsidy? What is the full annual cost including pathology?
• What side effects should I expect, when do they peak, and how will we manage them?
• What are we measuring besides weight — glucose, blood pressure, lipids, waist, function?
• What is the plan for maintaining muscle mass and nutrition while I lose weight?
• What happens to my weight and health markers if I stop? Is this long-term?
• How will supply interruptions be handled, and who is the registered prescriber?

FAQ

Is semaglutide approved in Australia? Yes — TGA-registered and prescription-only, with separate registrations for type 2 diabetes and chronic weight management. Registration is not the same as PBS subsidy; confirm the current subsidy position, which has changed more than once.

How much weight did people actually lose? About 14.9% on average over 68 weeks in STEP-1, in adults without diabetes, alongside lifestyle support. Individual results varied widely, and people with type 2 diabetes generally lost less.

What happens if I stop? Most of the weight returns — around two-thirds of it within about a year in the STEP-1 extension, with the metabolic improvements going too. Plan for this before you start.

Are compounded versions the same thing? No, and this is the most important safety point on this page. Compounded copies are not TGA-evaluated for identity, purity, sterility or strength, and pharmacy compounding of GLP-1 receptor agonists was prohibited in Australia in late 2024. Counterfeit product has also been detected — including pens containing insulin rather than semaglutide. Read compounded vs registered before considering any non-registered source.

How does it compare with tirzepatide? Tirzepatide acts on two receptor pathways rather than one and produced greater average weight loss head-to-head. Semaglutide currently has the more mature cardiovascular outcome data. Semaglutide vs tirzepatide compares them properly; the right choice is individual and clinical.

Where should I start? With a doctor who will assess your full cardiometabolic picture rather than sell you a product. Once you understand what you are actually treating, you can compare doctor-supervised weight management clinics, take the right questions into the consultation, and check your prescriber is registered.